Julie Graff

Associate Professor

  • 716 Citations
  • 11 h-Index
20072019
If you made any changes in Pure, your changes will be visible here soon.

Research Output 2007 2019

  • 716 Citations
  • 11 h-Index
  • 29 Article
  • 5 Review article
  • 1 Editorial
2019
1 Citation (Scopus)
Genetic Testing
Prostatic Neoplasms
Clinical Trials
Genetic Counseling
Neoplasms
1 Citation (Scopus)

MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer

Nickols, N. G., Nazarian, R., Zhao, S. G., Tan, V., Uzunangelov, V., Xia, Z., Baertsch, R., Neeman, E., Gao, A. C., Thomas, G., Howard, L., De Hoedt, A. M., Stuart, J., Goldstein, T., Chi, K., Gleave, M. E., Graff, J., Beer, T. T., Drake, J. M., Evans, C. P. & 11 others, Aggarwal, R., Foye, A., Feng, F. Y., Small, E. J., Aronson, W. J., Freedland, S. J., Witte, O. N., Huang, J., Alumkal, J., Reiter, R. E. & Rettig, M. B., Jan 1 2019, In : Prostate Cancer and Prostatic Diseases.

Research output: Contribution to journalArticle

Open Access
Castration
Mitogen-Activated Protein Kinase Kinases
Prostatic Neoplasms
Therapeutics
Phosphotransferases

The evolution and understanding of skeletal complication endpoints in clinical trials of tumors with metastasis to the bone

Hussain, A., Lee, R. J., Graff, J. & Halabi, S., Jul 1 2019, In : Critical Reviews in Oncology/Hematology. 139, p. 108-116 9 p.

Research output: Contribution to journalReview article

Open Access
Quality of Life
Clinical Trials
Neoplasm Metastasis
Bone and Bones
Survival
2018
200 Citations (Scopus)

Apalutamide treatment and metastasis-free survival in prostate cancer

Smith, M. R., Saad, F., Chowdhury, S., Oudard, S., Hadaschik, B. A., Graff, J., Olmos, D., Mainwaring, P. N., Lee, J. Y., Uemura, H., Lopez-Gitlitz, A., Trudel, G. C., Espina, B. M., Shu, Y., Park, Y. C., Rackoff, W. R., Yu, M. K. & Small, E. J., Apr 12 2018, In : New England Journal of Medicine. 378, 15, p. 1408-1418 11 p.

Research output: Contribution to journalArticle

Prostatic Neoplasms
Placebos
Neoplasm Metastasis
Survival
Castration
15 Citations (Scopus)

Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial

Saad, F., Cella, D., Basch, E., Hadaschik, B. A., Mainwaring, P. N., Oudard, S., Graff, J., McQuarrie, K., Li, S., Hudgens, S., Lawson, J., Lopez-Gitlitz, A., Yu, M. K., Smith, M. R. & Small, E. J., Oct 1 2018, In : The Lancet Oncology. 19, 10, p. 1404-1416 13 p.

Research output: Contribution to journalArticle

Castration
Prostatic Neoplasms
Placebos
Quality of Life
Androgens

Gonadotropin-releasing hormone antagonists in prostate cancer

Kittai, A. S., Blank, J. & Graff, J., Jan 1 2018, In : ONCOLOGY (United States). 32, 12, p. 599-606 8 p.

Research output: Contribution to journalReview article

Hormone Antagonists
Gonadotropin-Releasing Hormone
Prostatic Neoplasms
Castration
Androgens
2017
8 Citations (Scopus)

Antibody-mediated neutralization of soluble MIC significantly enhances CTLA4 blockade therapy

Zhang, J., Liu, D., Li, G., Staveley-O'Carroll, K. F., Graff, J., Li, Z. & Wu, J. D., May 1 2017, In : Science advances. 3, 5, e1602133.

Research output: Contribution to journalArticle

CTLA-4 Antigen
Antibodies
Therapeutics
Colitis
Neoplasms
10 Citations (Scopus)
Androgens
Survivors
Prostatic Neoplasms
Odds Ratio
Therapeutics
7 Citations (Scopus)

High-Dose Abiraterone Acetate in Men With Castration Resistant Prostate Cancer

Friedlander, T. W., Graff, J., Zejnullahu, K., Anantharaman, A., Zhang, L., Paz, R., Premasekharan, G., Russell, C., Huang, Y., Kim, W., Aggarwal, R. R., Lin, A. M., Fong, L., Alumkal, J., Beer, T. T., Sharifi, N., Alyamani, M., Dittamore, R., Small, E. J., Paris, P. L. & 1 others, Ryan, C. J., 2017, (Accepted/In press) In : Clinical Genitourinary Cancer.

Research output: Contribution to journalArticle

Castration
Prostatic Neoplasms
Prostate-Specific Antigen
Therapeutics
Androgens
1 Citation (Scopus)

Predictors of response and resistance to checkpoint inhibitors in solid tumors

Rao, S. V., Moran, A. E. & Graff, J., Dec 1 2017, In : Annals of Translational Medicine. 5, 23, 468.

Research output: Contribution to journalEditorial

Neoplasms
2 Citations (Scopus)

Should Chemotherapy Be Used in Nonmetastatic Prostate Cancer?

Graff, J., Alumkal, J. & Beer, T. T., Jan 1 2017, In : JAMA oncology. 3, 1, p. 11-12 2 p.

Research output: Contribution to journalArticle

Taxoids
Disease-Free Survival
Prostatic Neoplasms
Neoplasm Metastasis
Drug Therapy
2016
11 Citations (Scopus)

Cyclooxygenase-2 (COX-2) inhibition for prostate cancer chemoprevention: Double-blind randomised study of pre-prostatectomy celecoxib or placebo

Flamiatos, J. F., Beer, T. T., Graff, J., Eilers, K. M., Tian, W., Sekhon, H. S. & Garzotto, M., 2016, (Accepted/In press) In : BJU International.

Research output: Contribution to journalArticle

Celecoxib
Chemoprevention
Cyclooxygenase 2
Prostatectomy
Double-Blind Method
7 Citations (Scopus)

Docetaxel and mitoxantrone before radical prostatectomy in men with high-risk prostate cancer: 10-year follow-up and immune correlates

Bergstrom, C. P., Ruffell, B., Ho, C. M. T., Higano, C. S., Ellis, W. J., Garzotto, M., Beer, T. T. & Graff, J., Sep 23 2016, (Accepted/In press) In : Anti-Cancer Drugs.

Research output: Contribution to journalArticle

docetaxel
Mitoxantrone
Prostatectomy
Prostatic Neoplasms
Recurrence
152 Citations (Scopus)

Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer

Graff, J., Alumkal, J., Drake, C. G., Thomas, G., Redmond, W. L., Farhad, M., Cetnar, J., Ey, F. F., Bergan, R., Slottke, R. & Beer, T. T., Aug 1 2016, In : Oncotarget. 7, 33, p. 52810-52817 8 p.

Research output: Contribution to journalArticle

Prostatic Neoplasms
Cell Death
Castration
Hypothyroidism
Biopsy
38 Citations (Scopus)

Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castrationresistant prostate cancer: Results from PREVAIL

Graff, J., Baciarello, G., Armstrong, A. J., Higano, C. S., Iversen, P., Flaig, T. W., Forer, D., Parli, T., Phung, D., Tombal, B., Beer, T. T. & Sternberg, C. N., Feb 1 2016, In : Annals of Oncology. 27, 2, p. 286-294 9 p., mdv542.

Research output: Contribution to journalArticle

Prostatic Neoplasms
Safety
Drug Therapy
Castration
Androgen Receptors
4 Citations (Scopus)
Castration
Prostatic Neoplasms
Quality of Life
Placebos
Hot Flashes
3 Citations (Scopus)

Metastatic prostate cancer in 2015: The new and the old that is new again

Graff, J. & Beer, T. T., Feb 1 2016, In : Nature Reviews Clinical Oncology. 13, 2, p. 73-74 2 p.

Research output: Contribution to journalArticle

Hormonal Antineoplastic Agents
Castration-Resistant Prostatic Neoplasms
Antineoplastic Combined Chemotherapy Protocols
Molecular Targeted Therapy
Androgen Antagonists
10 Citations (Scopus)

Open-label, multicenter, phase 1 study of alisertib (MLN8237), an aurora A kinase inhibitor, with docetaxel in patients with solid tumors

Graff, J., Higano, C. S., Hahn, N. M., Taylor, M., Zhang, B., Zhou, X., Venkatakrishnan, K., Leonard, E. J. & Sarantopoulos, J., Aug 15 2016, In : Cancer. 122, 16, p. 2524-2533 10 p.

Research output: Contribution to journalArticle

docetaxel
Aurora Kinase A
Neoplasms
Pharmacokinetics
Fever
6 Citations (Scopus)

Treatment of Nonmetastatic Castration-Resistant Prostate Cancer

Luo, J., Beer, T. T. & Graff, J., Apr 1 2016, In : Oncology (Williston Park, N.Y.). 30, 4, p. 336-344 9 p.

Research output: Contribution to journalReview article

Castration
Prostatic Neoplasms
Disease Progression
Therapeutics
Clinical Trials
2015
68 Citations (Scopus)

A phase II study of sulforaphane-rich broccoli sprout extracts in men with recurrent prostate cancer

Alumkal, J., Slottke, R., Schwartzman, J., Cherala, G., Munar, M., Graff, J., Beer, T. T., Ryan, C., Koop, D., Gibbs, A., Gao, L., Flamiatos, J. F., Tucker, E., Kleinschmidt, R. & Mori, M. T., Apr 1 2015, In : Investigational New Drugs. 33, 2, p. 480-489 10 p.

Research output: Contribution to journalArticle

Brassica
Prostatic Neoplasms
Vegetables
Diet
Prostate
5 Citations (Scopus)
docetaxel
Castration
Proxy
Granulocyte-Macrophage Colony-Stimulating Factor
Prednisone
18 Citations (Scopus)
Meta-Analysis
Prostatic Neoplasms
Depression
Psychotherapy
Massage
7 Citations (Scopus)

Pooled Analysis of C-Reactive Protein Levels and Mortality in Prostate Cancer Patients

Graff, J., Beer, T. T., Liu, B., Sonpavde, G. & Taioli, E., Aug 1 2015, In : Clinical Genitourinary Cancer. 13, 4, p. e217-e221

Research output: Contribution to journalArticle

C-Reactive Protein
Prostatic Neoplasms
Mortality
Confidence Intervals
Survival
6 Citations (Scopus)

Reducing Skeletal-Related Events in Metastatic Castration-Resistant Prostate Cancer

Graff, J. & Beer, T. T., Jun 1 2015, In : Oncology (Williston Park, N.Y.). 29, 6, p. 416-423 8 p.

Research output: Contribution to journalReview article

zoledronic acid
Castration
Prostatic Neoplasms
Costs and Cost Analysis
Radium
5 Citations (Scopus)

Safety and effectiveness of enzalutamide in men with metastatic, castration-resistant prostate cancer

Graff, J., Gordon, M. J. & Beer, T. T., Apr 1 2015, In : Expert Opinion on Pharmacotherapy. 16, 5, p. 749-754 6 p.

Research output: Contribution to journalArticle

Castration
Prostatic Neoplasms
Safety
Drug Therapy
Disease-Free Survival
3 Citations (Scopus)

Should docetaxel be administered earlier in prostate cancer therapy?

Graff, J. & Beer, T. T., Sep 2 2015, In : Expert Review of Anticancer Therapy. 15, 9, p. 977-979 3 p.

Research output: Contribution to journalArticle

docetaxel
Taxoids
Antineoplastic Agents
Prostatic Neoplasms
Neoplasm Metastasis
2014
6 Citations (Scopus)
Castration
Prostatic Neoplasms
Drug Therapy
Radium
Population
20 Citations (Scopus)

Sipuleucel-T in the treatment of prostate cancer: An evidence-based review of its place in therapy

Graff, J. & Chamberlain, E. D., Dec 18 2014, In : Core Evidence. 10

Research output: Contribution to journalArticle

Prostatic Neoplasms
Castration
Therapeutics
Survival
Randomized Controlled Trials
19 Citations (Scopus)

Sustained complete response to CTLA-4 blockade in a patient with metastatic, castration-resistant prostate cancer

Graff, J., Puri, S., Bifulco, C. B., Fox, B. A. & Beer, T. T., May 1 2014, In : Cancer immunology research. 2, 5, p. 399-403 5 p.

Research output: Contribution to journalArticle

Castration
Prostate-Specific Antigen
Antibody Formation
Prostatic Neoplasms
3-hydroxyisobutyryl-CoA hydrolase
2013
16 Citations (Scopus)
Castration
Prostate-Specific Antigen
Prostatic Neoplasms
MDV 3100
sipuleucel-T
1 Citation (Scopus)
Androgen Receptors
Prostatic Neoplasms
Therapeutics
4 Citations (Scopus)

The role of C-reactive protein in prostate cancer

Graff, J. & Beer, T. T., Sep 15 2013, In : Cancer. 119, 18, p. 3262-3264 3 p.

Research output: Contribution to journalArticle

Tumor Biomarkers
C-Reactive Protein
Prostatic Neoplasms
Adenocarcinoma
2012
45 Citations (Scopus)

C-reactive protein as an adverse prognostic marker for men with castration-resistant prostate cancer (CRPC): Confirmatory results

Prins, R. C., Rademacher, B. L., Mongoue-Tchokote, S., Alumkal, J., Graff, J., Eilers, K. M. & Beer, T. T., Jan 2012, In : Urologic Oncology: Seminars and Original Investigations. 30, 1, p. 33-37 5 p.

Research output: Contribution to journalArticle

Castration
C-Reactive Protein
Prostatic Neoplasms
Survival
Proportional Hazards Models
2011
2 Citations (Scopus)

Toward predictors of survival in castration-resistant prostate cancer

Graff, J. & Beer, T. T., Sep 1 2011, In : Cancer. 117, 17, p. 3882-3884 3 p.

Research output: Contribution to journalArticle

Castration
Prostatic Neoplasms
Survival
Phase III Clinical Trials
2007
15 Citations (Scopus)
Androgens
Prostatic Neoplasms
Outcome Assessment (Health Care)
Survival
Neoplasms